Loading company
Neurocrine Biosciences Inc.
NBIX · Nasdaq · ·
Next earnings: October 27, 2026
$138.37-1.5%Sep 29 close
- 1M
- -10.2%
- 6M
- +7.5%
- 1Y
- -1.4%
- 5Y
- +45.8%
NBIX · Nasdaq · ·
Next earnings: October 27, 2026
$138.37-1.5%Sep 29 close
Neurocrine Biosciences Inc. is scheduled to report next on October 27, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $959M | $687.5M | +39.49% |
| Profit | $144.4M | $107.5M | +34.33% |
| Profit per share | $1.39 | $1.06 | +31.13% |
| Free Cash Flow | $128.6M | $89.5M | +43.69% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“Our second quarter performance demonstrates the power of a strategy designed to compound over time,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company’s diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, classic congenital adrenal hyperplasia, hyperphagia in Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Neurocrine Biosciences Inc.’s Item 2.02 8-K filed July 30, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Neurocrine Biosciences Inc. has no earnings call transcript available.